Show simple item record

dc.contributor.authorKhan, Parveen
dc.contributor.authorAbbas, Sayara
dc.contributor.authorPetit, B
dc.contributor.authorCaffrey, Robert
dc.contributor.authorMegram, Victoria
dc.contributor.authorMcGown, Alan T
dc.date.accessioned2010-01-28T13:51:56Z
dc.date.available2010-01-28T13:51:56Z
dc.date.issued1999-04-16
dc.identifier.citationDevelopment and validation of a high-performance liquid chromatographic assay using solid-phase extraction for the novel antitumor agent pancratistatin in human plasma. 1999, 726 (1-2):249-54 J. Chromatogr. B Biomed. Sci. Appl.en
dc.identifier.issn1387-2273
dc.identifier.pmid10348192
dc.identifier.doi10.1016/S0378-4347(99)00053-5
dc.identifier.urihttp://hdl.handle.net/10541/90768
dc.description.abstractThe stability of the experimental anti-tumour agent pancratistatin in human plasma has been investigated. A solid-phase extraction technique and an HPLC assay with external standards have been developed and validated. Extraction was performed using C18 cartridges and HPLC, analysis was performed on a 15 cm Hypersil BDS column using isocratic elution with 13% acetonitrile and aqueous solution of 1% (w/v) acetic acid. The lower limit of quantification for pancratistatin in 5% DMF-95% water was found to be 0.58 ng/ml (+/-10.58%) and 2.3 ng/ml (+/-9.2%) following extraction from human plasma. Mean recovery of 89.4% (+/-4.73%) was obtained over the concentration range 0.0023-9.45 microg/ml for a five day validation study. Pancratistatin was stable at room temperature in light or dark for at least 15 days, in the refrigerator at 4 degrees C for at least 16 days and in the freezer at -20 degrees C or -80 degrees C for at least 28 days. Under all conditions monitored, % recovery of pancratistatin from human plasma was greater than 95% and no evidence of degradation had occurred. There also was no loss of pancratistatin after three cycles of freezing and thawing.
dc.language.isoenen
dc.subject.meshAmaryllidaceae Alkaloids
dc.subject.meshAntineoplastic Agents, Phytogenic
dc.subject.meshChromatography, High Pressure Liquid
dc.subject.meshHumans
dc.subject.meshIsoquinolines
dc.subject.meshReproducibility of Results
dc.subject.meshSpectrophotometry, Ultraviolet
dc.titleDevelopment and validation of a high-performance liquid chromatographic assay using solid-phase extraction for the novel antitumor agent pancratistatin in human plasma.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Section of Drug Development and Imaging, Withington, Manchester, UK. pkhan@picr.man.ac.uken
dc.identifier.journalJournal of Chromatography. B, Biomedical Sciences and Applicationsen
html.description.abstractThe stability of the experimental anti-tumour agent pancratistatin in human plasma has been investigated. A solid-phase extraction technique and an HPLC assay with external standards have been developed and validated. Extraction was performed using C18 cartridges and HPLC, analysis was performed on a 15 cm Hypersil BDS column using isocratic elution with 13% acetonitrile and aqueous solution of 1% (w/v) acetic acid. The lower limit of quantification for pancratistatin in 5% DMF-95% water was found to be 0.58 ng/ml (+/-10.58%) and 2.3 ng/ml (+/-9.2%) following extraction from human plasma. Mean recovery of 89.4% (+/-4.73%) was obtained over the concentration range 0.0023-9.45 microg/ml for a five day validation study. Pancratistatin was stable at room temperature in light or dark for at least 15 days, in the refrigerator at 4 degrees C for at least 16 days and in the freezer at -20 degrees C or -80 degrees C for at least 28 days. Under all conditions monitored, % recovery of pancratistatin from human plasma was greater than 95% and no evidence of degradation had occurred. There also was no loss of pancratistatin after three cycles of freezing and thawing.


Files in this item

This item appears in the following Collection(s)

Show simple item record